Bio-Rad Laboratories, Inc.Class A (BIO)
NYSE Market Closed
Bio-Rad Laboratories, Inc. Class A represents the publicly traded Class A shares of Bio-Rad, a California-based supplier of tools, instruments and consumables used across healthcare testing and scientific research. The company serves two closely related markets: clinical diagnostics, where its systems help laboratories run and monitor medical tests, and life sciences, where researchers and biopharmaceutical manufacturers use its reagents, instruments and software to study biology and develop therapies.
In diagnostics, Bio-Rad is known for quality control products, immunohematology systems, diabetes testing, autoimmune testing and other specialized laboratory solutions. These products are used by hospitals, reference laboratories and blood banks that require reliable, standardized results. The recurring nature of controls, reagents and service support gives the business exposure to routine healthcare testing rather than one-off capital equipment sales alone.
Bio-Rad’s life sciences segment supplies technologies for protein analysis, cell biology, gene expression, chromatography, digital PCR and related research workflows. Its droplet digital PCR platform is a notable part of the portfolio, giving scientists a highly sensitive method for measuring nucleic acids in areas such as oncology research, infectious disease studies and bioprocess monitoring.
The company operates globally, with meaningful sales in the Americas, Europe and Asia-Pacific. Bio-Rad also holds a large strategic investment in Sartorius, a major German supplier to the bioprocessing industry, which adds an additional link to biologics manufacturing trends. For investors, Bio-Rad is a diversified life science and diagnostics company with exposure to laboratory automation, biomedical research and long-term demand for higher-quality testing.
Last updated
- Market Cap
- 8.23B
- P/E
- 48.75
- P/FCF
- 23.04
- P/S
- 3.18
- Enterprise Value
- 8.92B
- Sector
- —
- Industry
- Laboratory Analytical Instruments
- Address
- 1000 ALFRED NOBEL DRIVE, HERCULES, CA, 94547
Cancer Biomarkers Market Outlook 2026–2031: Growing at a 8.65% CAGR, Driven by Precision Oncology and Early Detection Demand, Says Mordor Intelligence
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Drug Screening Market Trends 2026–2031: Chromatography and Mass Spectrometry Held a 44.77% Share in 2025 Amid Growing Demand for Advanced Testing, Reports Mordor Intelligence
Next Generation Sequencing Market Size to Worth USD 103.24 Bn by 2035
Custom Antibody Market to Reach USD 1,297.65 Million by 2033, Growing Demand for Precision Medicine and Targeted Therapies to Drive the Market – SNS Insider
$43.36 Bn Autism Spectrum Disorder Diagnostics Global Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029F, 2034F
IVD Diagnostic Molecule Raw Enzymes Market Forecast to Grow at 7.13% CAGR by 2034
Blood Group Typing Global Market Overview 2025-2030: PCR-based Techniques Command the Largest Share
Human Combinatorial Antibody Libraries Market to Surge USD 189.57 Million by 2034, Reports Towards Healthcare
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers
Food Pathogen Testing Market Trends, Analysis, and Forecast 2025-2034 | CRISPR and Lab-on-a-Chip Technologies Set to Revolutionize Pathogen Detection
Epigenetics Market Anticipated to Achieve 11.8% CAGR
Antibody and Protein Labeling Kits Market Outlook, Trends, Growth and Opportunities | Exactitude Consultancy
Thyroid Function Testing Market to Hit USD 2.74 Billion by 2032, Driven by Rising Thyroid Disorder Prevalence and Technological Advancements – SNS Insider
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Heart Attack Diagnostics Market Size to Hit USD 21.38 Billion by 2032, Fueled by Advances in Rapid Testing and AI-Driven Tools – SNS Insider
Blood Typing Analysis Report 2024: Market Set to Surge to $6.50 Billion by 2034, PCR and Microarray Techniques Pave the Way
Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight
Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™.
Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Report 2025: Key Trends, Major Players, Opportunities, Strategies, M&As, 2018-2023, 2028F, 2033F
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 8.23B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 8.92B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 48.75
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.2
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 3.18
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 38.74
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 3.45
- EPS
- 6.31
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 23.04
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 16.12
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 357.2M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 2.46%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 1.72%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.18
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.21
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.37
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.55
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 461.83K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 307.47
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 592.1M | 693.2M | 653M | 651.6M | 585.4M |
| Gross profit | 309.4M | 345.2M | 343.4M | 345.3M | 306M |
| Operating income | 34.1M | 53.9M | 65.3M | 77.1M | 23.7M |
| EBITDA | 34.1M | 53.9M | 65.3M | 77.1M | 23.7M |
| Net income | -527.1M | 720M | -341.9M | 317.8M | 64M |
| Basic EPS | -19.55 | 26.41 | -12.7 | 11.67 | 2.29 |
| Diluted EPS | -19.55 | 26.39 | -12.7 | 11.67 | 2.29 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 9.79B | 10.58B | 9.7B | 10.21B | 9.53B |
| Total liabilities | 2.94B | 3.12B | 2.96B | 3.09B | 2.85B |
| Total equity | 6.85B | 7.45B | 6.74B | 7.13B | 6.68B |
| Cash & equivalents | 507.2M | 529.8M | 395.8M | 369.3M | 521.4M |
| Current assets | 2.94B | 2.91B | 2.84B | 2.81B | 3.04B |
| Current liabilities | 917M | 517M | 522.3M | 548.9M | 506.6M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 108.1M | 164.9M | 120.9M | 116.5M | 129.9M |
| Investing cash flow | -93.2M | -34.2M | -43M | -115.4M | 2.9M |
| Financing cash flow | -44M | 3.3M | -52.5M | -136.3M | -97.7M |
| Change in cash | -23.2M | 134M | 26.5M | -151.4M | 33.3M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | SD — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 144 — BIO-RAD LABORATORIES, INC. | View Filing | |
| form 4 | Form 4 — ENGELHARDT EVA ANETTE | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 8-K — BIO-RAD LABORATORIES, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Lakkaraju Roop Kalyan | View Filing | |
| form 4 | Form 4 — Lakkaraju Roop Kalyan | View Filing | |
| form 4 | Form 4 — Lakkaraju Roop Kalyan | View Filing | |
| form 4 | Form 4 — ENLOE COURTNEY C | View Filing | |
| form 4 | Form 4 — ENLOE COURTNEY C | View Filing | |
| form 4 | Form 4 — ENLOE COURTNEY C | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| form 4 | Form 4 — EDWARDS JEFFREY L | View Filing | |
| form 4 | Form 4 — EDWARDS JEFFREY L | View Filing | |
| form 4 | Form 4 — EDWARDS JEFFREY L | View Filing | |
| form 4 | Form 4 — Hinckley Greg K | View Filing | |
| form 4 | Form 4 — Hinckley Greg K | View Filing | |
| form 4 | Form 4 — Hinckley Greg K | View Filing | |
| form 4 | Form 4 — PINKSTON ARNOLD A | View Filing | |
| form 4 | Form 4 — PINKSTON ARNOLD A | View Filing | |
| form 4 | Form 4 — PINKSTON ARNOLD A | View Filing | |
| form 4 | Form 4 — PEI MELINDA LITHERLAND | View Filing | |
| form 4 | Form 4 — PEI MELINDA LITHERLAND | View Filing | |
| form 4 | Form 4 — PEI MELINDA LITHERLAND | View Filing | |
| edgar index | SCHEDULE 13G/A — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | DEF 14A — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | ARS — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 8-K — BIO-RAD LABORATORIES, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-K — BIO-RAD LABORATORIES, INC. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — BIO-RAD LABORATORIES, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 144 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 144 — BIO-RAD LABORATORIES, INC. | View Filing | |
| form 4 | Form 4 — BARRY JAMES | View Filing | |
| edgar index | SCHEDULE 13D/A — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | SCHEDULE 13D/A — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 8-K — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 10-Q — BIO-RAD LABORATORIES, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13D/A — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | SCHEDULE 13D/A — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| form 4 | Form 4 — DiVincenzo Jonathan P. | View Filing | |
| form 4 | Form 4 — DiVincenzo Jonathan P. | View Filing | |
| form 4 | Form 4 — DiVincenzo Jonathan P. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| form 4 | Form 4 — EVRAN SEDAT | View Filing | |
| form 4 | Form 4 — EVRAN SEDAT | View Filing | |
| form 4 | Form 4 — EVRAN SEDAT | View Filing | |
| edgar index | SCHEDULE 13G/A — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 8-K — BIO-RAD LABORATORIES, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing | |
| edgar index | 4 — BIO-RAD LABORATORIES, INC. | View Filing |